At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
ADM03820 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults
In Brief
A Phase 1 clinical trial evaluating ADM03820 and Placebo for SARS-CoV-2. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
This is a phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of ADM03820 administered as IM injections in healthy adults for the prevention of COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
CollaboratorsEnabling Biotechnologies (EB)
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionOct 2023
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartDec 4, 2020
Primary CompletionOct 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.7 years ago
Interventions
ADM03820drug
ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
Placeboother
Placebo